1. A phase 2, multicentre, open‐label trial (ACE‐LY‐003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma. (21st July 2022) Authors: Strati, Paolo; Coleman, Morton; Champion, Rebecca; Ma, Shuo; Patti, Caterina; Levy, Moshe Y.; Lossos, Izidore S.; Geethakumari, Praveen Ramakrishnan; Lam, Selay; Calvo, Roser; Higgins, Kara; Budde, Lihua E. Journal: British journal of haematology Issue: Volume 199:Number 1(2022) Page Start: 76 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Phase 1/2 study of acalabrutinib and the PI3K delta inhibitor ACP-319 in relapsed/refractory B-cell Non-Hodgkin lymphoma. Issue 7 (7th June 2022) Authors: Barr, Paul M.; Smith, Stephen D.; Roschewski, Mark J.; O'Brien, Susan M.; Sharman, Jeff P.; Melear, Jason M.; Patel, Priti; Calvo, Roser; Yang, Helen; Spurgeon, Stephen E. Journal: Leukemia & lymphoma Issue: Volume 63:Issue 7(2022) Page Start: 1728 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗